Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis-Reference-Cited by-同舟云学术

Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis

Published:2019-07-16 Issue:5 Volume:48 Page:375-382
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Behrens F¹²,Koehm M¹²,Schwaneck EC³,Schmalzing M³,Wittig BM⁴,Gnann H⁵,Greger G⁴,Tony H-P³,Burkhardt H¹²

Affiliation:

1. Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

2. Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main, Germany

3. Medizinische Klinik und Poliklinik 2, Department of Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany

4. AbbVie Germany GmbH & Co. KG, Wiesbaden, Germany

5. Department of Biostatistics, GKM, Munich, Germany

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://tandfonline.com/doi/pdf/10.1080/03009742.2019.1600717

Reference26 articles.

1. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

2. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature

3. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

4. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Tumor Necrosis Factor Inhibitor;Arthritis & Rheumatology;2023-05-24

2. Ustekinumab with or without methotrexate for psoriatic arthritis?;The Lancet Rheumatology;2023-01

3. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial;The Lancet Rheumatology;2023-01

4. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study;The Lancet Rheumatology;2022-04

5. Is there still a place for methotrexate in severe psoriatic arthritis?;Therapeutic Advances in Musculoskeletal Disease;2022-01